Immunome, Inc. Comprehensive Income
Immunome, Inc. (IMNM) reported Comprehensive Income of -$73.46 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-11
- Immunome, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$73.46M.
- Immunome, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$53.84M.
- Immunome, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$69.90M.
- Immunome, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$57.43M.
- Immunome, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$212.45M.
- Immunome, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$292.93M.
- Immunome, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$106.78M.
- Immunome, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$37.52M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$73.46M 10-Q · filed 2026-08-11 | -$127.30M 10-Q · filed 2026-08-11 | -$197.20M derived: sum of 3 quarters · filed 2026-08-11 | -$254.63M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$53.84M 10-Q · filed 2026-05-12 | -$123.74M derived: sum of 2 quarters · filed 2026-05-12 | -$181.17M derived: sum of 3 quarters · filed 2026-05-12 | -$224.59M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$69.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$127.33M derived: sum of 2 quarters · filed 2026-03-03 | -$170.75M derived: sum of 3 quarters · filed 2026-08-11 | -$212.45M 10-K · filed 2026-03-03 |
| 2025-09-30 | -$57.43M 10-Q · filed 2025-11-06 | -$100.85M derived: sum of 2 quarters · filed 2026-08-11 | -$142.55M 10-Q · filed 2025-11-06 | -$222.81M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$43.42M 10-Q · filed 2026-08-11 | -$85.12M 10-Q · filed 2026-08-11 | -$165.38M derived: sum of 3 quarters · filed 2026-08-11 | -$212.41M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$41.70M 10-Q · filed 2026-05-12 | -$121.96M derived: sum of 2 quarters · filed 2026-05-12 | -$168.99M derived: sum of 3 quarters · filed 2026-05-12 | -$205.12M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$80.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$127.29M derived: sum of 2 quarters · filed 2026-03-03 | -$163.42M derived: sum of 3 quarters · filed 2026-03-03 | -$292.93M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$47.03M 10-Q · filed 2025-11-06 | -$83.16M derived: sum of 2 quarters · filed 2025-11-06 | -$212.67M 10-Q · filed 2025-11-06 | -$305.28M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$36.12M 10-Q · filed 2025-08-06 | -$165.63M 10-Q · filed 2025-08-06 | -$258.25M derived: sum of 3 quarters · filed 2025-08-06 | -$262.59M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$129.51M 10-Q · filed 2025-05-12 | -$222.12M derived: sum of 2 quarters · filed 2025-05-12 | -$226.47M derived: sum of 3 quarters · filed 2025-05-12 | -$232.02M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$92.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | -$96.96M derived: sum of 2 quarters · filed 2025-03-19 | -$102.51M derived: sum of 3 quarters · filed 2025-03-19 | -$106.78M 10-K · filed 2025-03-19 |
| 2023-09-30 | -$4.34M 10-Q · filed 2024-11-13 | -$9.90M derived: sum of 2 quarters · filed 2024-11-13 | -$14.17M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$5.56M 10-Q · filed 2024-08-12 | -$9.83M 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | -$4.27M 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | -$37.52M 10-K · filed 2024-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |